Drugs in Pipeline
5
Phase 3 Programs
5
Upcoming Catalysts
3
Next Catalyst
Jan 31, 2026
| Drug Name | Phase |
|---|---|
KSI-101 | Phase 3 |
KSI-301 | Phase 3 |
Tarcocimab | Phase 3 |
Tarcocimab tedromer | Phase 3 |
Aflibercept | Phase 3 |
3 upcoming, 0 past
Primary completion for Tarcocimab trial (NCT06270836) in Diabetic Retinopathy
SourcePrimary completion for KSI-101 trial (NCT06990399) in Macular Edema Secondary to Inflammation
SourcePrimary completion for Tarcocimab tedromer trial (NCT06556368) in Wet Age-related Macular Degeneration
Source